LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases —a phase II study
ConclusionsPanitumumab and FOLFIRI as perioperative therapy for resectable CLM result in a radiological objective response rate in 65.7% of patients with a manageable grade 3 diarrhea rate of 14.3%. Median PFS was 13.2 months, and the 24-month OS rate was 73.3%. These data are insufficient to widen the indication of panitumumab from the unresectable setting to the setting of resectable CLM.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Austria Health | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Eloxatin | Liver | Pulmonary Thromboembolism | Sarcomas | Skin | Stroke | Study | Toxicology | Urology & Nephrology | Vitamin B9 | Women